IONS (Ionis Pharmaceuticals) Shiller PE Ratio: (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IONS Ionis Pharmaceuticals Inc IONS
69 GF Score
Price $55.89
GF Value $48.20
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Ionis Pharmaceuticals  (NAS:IONS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Ionis Pharmaceuticals Shiller PE Ratio Related Terms


Ionis Pharmaceuticals Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Shiller PE Ratio Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ionis Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

IONS vs APGE, CYTK, KRYS: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Ionis Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ionis Pharmaceuticals Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ionis Pharmaceuticals's Shiller PE Ratio falls into.


IONS
69GF Score
Ionis Pharmaceuticals Inc IONS
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ionis Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Ionis Pharmaceuticals's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Ionis Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.69/333.9520*333.9520
=-0.690

Current CPI (Jun. 2026) = 333.9520.

Ionis Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 0.060 241.428 0.083
201612 0.210 241.432 0.290
201703 0.070 243.801 0.096
201706 -0.020 244.955 -0.027
201709 -0.020 246.819 -0.027
201712 0.020 246.524 0.027
201803 -0.010 249.554 -0.013
201806 -0.290 251.989 -0.384
201809 -0.030 252.439 -0.040
201812 2.210 251.233 2.938
201903 0.620 254.202 0.815
201906 -0.010 256.143 -0.013
201909 0.180 256.759 0.234
201912 1.280 256.974 1.663
202003 -0.280 258.115 -0.362
202006 -0.180 257.797 -0.233
202009 -0.180 260.280 -0.231
202012 -2.440 260.474 -3.128
202103 -0.640 264.877 -0.807
202106 -0.570 271.696 -0.701
202109 -0.580 274.310 -0.706
202112 1.410 278.802 1.689
202203 -0.460 287.504 -0.534
202206 -0.740 296.311 -0.834
202209 -0.330 296.808 -0.371
202212 -0.370 296.797 -0.416
202303 -0.870 301.836 -0.963
202306 -0.600 305.109 -0.657
202309 -1.030 307.789 -1.118
202312 -0.060 306.746 -0.065
202403 -0.980 312.332 -1.048
202406 -0.450 314.175 -0.478
202409 -0.950 315.301 -1.006
202412 -0.660 315.605 -0.698
202503 -0.930 319.799 -0.971
202506 0.700 322.561 0.725
202509 -0.800 324.800 -0.823
202512 -1.410 324.054 -1.453
202603 -0.560 330.213 -0.566
202606 -0.690 333.952 -0.690

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Ionis Pharmaceuticals (IONS) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of $55.89 is trading 15.9% above its estimated GF Value™ of $48.20. GuruFocus considers Ionis Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for IONS:

  • Shiller PE Ratio:
  • GF Value™: $48.20 vs. price of $55.89 (15.9% above fair value)
  • GF Score™: 69/100 with 4 warning signs

No single metric tells the full story. See the IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ionis Pharmaceuticals Business Description

Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
69GF Score

Get the complete analysis for IONS

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$55.89
Price
$48.20
GF Value